PHGN Stock Overview
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pharming Group N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.71 |
| 52 Week High | €1.19 |
| 52 Week Low | €0.65 |
| Beta | 0.81 |
| 11 Month Change | -7.94% |
| 3 Month Change | -1.74% |
| 1 Year Change | -33.00% |
| 33 Year Change | -4.44% |
| 5 Year Change | -51.00% |
| Change since IPO | -99.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHGN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.3% | -0.7% | -0.02% |
| 1Y | -33.0% | -17.2% | 8.2% |
Return vs Industry: PHGN underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: PHGN underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| PHGN volatility | |
|---|---|
| PHGN Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: PHGN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PHGN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 382 | Simon de Vries | www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pharming Group N.V. Fundamentals Summary
| PHGN fundamental statistics | |
|---|---|
| Market cap | €485.70m |
| Earnings (TTM) | -€17.12m |
| Revenue (TTM) | €274.40m |
1.8x
P/S Ratio-28.4x
P/E RatioIs PHGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHGN income statement (TTM) | |
|---|---|
| Revenue | US$285.75m |
| Cost of Revenue | US$30.30m |
| Gross Profit | US$255.44m |
| Other Expenses | US$273.26m |
| Earnings | -US$17.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 89.39% |
| Net Profit Margin | -6.24% |
| Debt/Equity Ratio | 42.3% |
How did PHGN perform over the long term?
See historical performance and comparison